Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 28,385.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,385.71% |
| Mar 31, 2026 | -222.23% |
| Dec 31, 2025 | -681.94% |
| Sep 30, 2025 | -100.31% |
| Jun 30, 2025 | 99.84% |
| Mar 31, 2025 | 5,107.89% |
| Dec 31, 2024 | -72.95% |
| Sep 30, 2024 | 83.22% |
| Jun 30, 2024 | -145.89% |
| Mar 31, 2024 | -100.25% |
| Dec 31, 2023 | 290.94% |
| Sep 30, 2023 | 105.19% |
| Jun 30, 2023 | 19,851.55% |
| Mar 31, 2023 | 33,634.78% |
| Dec 31, 2022 | -3,394.52% |
| Sep 30, 2022 | -60,067.65% |
| Jun 30, 2022 | 15.65% |
| Mar 31, 2022 | -100.46% |
| Dec 31, 2021 | -116.19% |
| Sep 30, 2021 | -138.20% |